Price
No data yet.
Social Signal Score
Revenue
$9.63M+349.51%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Phillip Chan
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 129
- Beta
- 1.35
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -12.15
Financials
Revenue
$9.63M+349.5%Net Income
$-4.42MEBITDA
$-3.35MFree Cash Flow
$-1.77MEPS (diluted)
$-0.07Shares Outstanding (diluted)
62.81M+146.8%Operating Expenses
$9.42MCash & Debt
$4.41MReturn of Capital
$0.00Revenue by Segment (annual)
$5.33MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $37.06M | $-8.20M | $-0.13 |
| 2024 | $35.59M | $-20.72M | $-0.38 |
| 2023 | $31.08M | $-29.25M | $-0.65 |
| 2022 | $34.69M | $-32.81M | $-0.75 |
| 2021 | $40.11M | $-24.56M | $-0.57 |
| 2020 | $39.45M | $-7.84M | $-0.20 |
| 2019 | $22.77M | $-19.27M | $-0.60 |
| 2018 | $20.25M | $-17.21M | $-0.56 |
| 2017 | $13.38M | $-8.46M | $-0.31 |
| 2016 | $8.21M | $-11.94M | $-0.47 |
| 2015 | $4.06M | $-8.13M | $-0.33 |
| 2014 | $3.15M | $-9.32M | $-0.65 |
| 2013 | $821.8K | $-4.68M | $-0.50 |
| 2012 | $151.6K | $-3.66M | $-0.46 |
Valuation
CTSOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (2)
- Newsnewsfilecorp.com·5h ago·Neutral
…y Capital Solutions 2026 Disruptive Growth & Life Sciences Conference Princeton, New Jersey--(Newsfile Corp. - September 4, 2026) - CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, is pleased to announce its participation at the upcoming Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference, taking place September 9-10, 2026, in New York City. Dr. Phillip …
View source ↗ - Newsprnewswire.com·1d ago·Neutral
… Effective and Trade on Split-Adjusted Basis at the Market Open on September 8, 2026 PRINCETON, N.J., Sept. 3, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that it will effect a one-for-twenty (1:20) reverse stock split (the "Reverse Stock Split") of its common stock, par value $0.001 per share (the "Common Stock").
View source ↗
Earnings
Thu, Nov 12(in 2 months)
Consensus estimate $-0.05 per share
Typical surprise -33.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.07 vs $-0.04miss
- Wed, May 13$-0.08 vs $-0.06miss
- Wed, Mar 25$-0.09 vs $-0.05miss
- Thu, Nov 13$-0.04 vs $-0.06beat
- Thu, Aug 7$-0.05 vs $-0.07beat
- Wed, May 14$-0.06 vs $-0.08beat
Estimates and results for CTSO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CTSO officers and directors.
- Bought
- $665k
- Sold
- —
23 trades
0 trades
- Mariani Peter Jbought
- Chan Phillip P.bought
- Chan Phillip P.bought
- Mariani Peter Jbought
- Mariani Peter Jbought
- Mariani Peter Jbought
- Sobel Alan D.bought
- Sobel Alan D.bought
77 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.